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serum creatinine of 1.59 mg/dl and a median urinary protein excretion of 17
g/moL creatinine. Patients had absent in vitro lymphocyte reactivity against
stimulatory donor blood cells while reactivity against third party cells was
preserved as an indication of continued donor-specific unresponsiveness.
CD19+CD24hiCD38hi and IL10+CD19+CD24hiCD38hi Breg were with 2.2/µl
and 1.0/µl, respectively, strikingly higher than the 0.0/µl (P < 0.001) and
0.0/µl (P < 0.001) in transplanted controls and in the range of the numbers
of healthy individuals (N = 34: 2.4/µl, P = 0.73, and 0.8/µl, P = 0.60). In
addition, significantly higher Breg numbers were found for CD1d+
(P = 0.0071), CD19+CD38+CD147+CD1d+ (P = 0.0071), CD19+CD25+
(P = 0.0077), CD19+CD25+CD73+CD71+ (P = 0.013), CD19+CD25+CD73-
CD71+ (P = 0.0011), CD19+CD24hiCD27+ memory (P = 0.029), and
IL10+CD19+CD24hiCD27+ memory Breg (P = 0.042).
Conclusion: Donor-specific immunosuppression after MIC infusion is long-
lasting and is associated with a striking increase in Breg at various stages
of B cell development, including memory Breg.
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Background: Regulatory T cell therapy is an emerging treatment in the
field of clinical transplantation with the potential to improve short and long-
term transplant outcomes. A critical aspect of these studies is generating an
understanding of how infused regulatory T cells impact on the recipient
immune response to alloantigen including within the graft.
Methods: 8 Patients receiving regulatory T cell infusion as part of a phase
1 clinical trial underwent a protocol biopsy at 8 months post-transplant.
Observed immune infiltrates were compared with those from patients experi-
encing an acute cell mediated rejection episode and infiltrates seen in rou-
tine surveillance biopsies from patients with clinically stable graft function.
Biopsies were analysed by routine immunohistochemistry. NanoString
GeoMX digital spatial profiling of protein and mRNA expression was per-
formed to greater characterise immune infiltrates.
Results: Routine histology demonstrated the presence of unique cellular
infiltrates in all patients treated with regulatory T cells that were dense and
remarkably focal in nature. 4 colour immunofluorescence (figure) demon-
strated such infiltrates contain a greater proportion of CD4+ FOXP3+ cells
than infiltrates seen in patients experiencing a rejection episode (4.45% Vs
1.6%, P < 0.001). Principle component analysis revealed that protein
expression and RNA expression patterns clearly demonstrate distinct infil-
trates in rejection Vs cell therapy biopsies. Further interrogation revealed
significantly different expression of cell markers such as CD3, CD45, CD14,
CD68 and CD20 as well as functional markers such as Ki67, Granzyme B,
CXCL9 and CXCL10 in infiltrates noted in biopsies from patients receiving
cell therapy compared to those from patients experiencing a rejection epi-
sode and surveillance biopsies in patients with stable graft function.
Conclusions: Infiltrates from patients treated with cell therapy demonstrate
elevated FOXP3 expression and a more quiescent or tolerant microenviron-
ment than seen in infiltrates associated with rejection raising the possibility
of regulatory T cells mediating intra-graft immune regulation. We demon-
strate that infiltrates in all three clinical scenarios demonstrate unique prop-
erties and represent distinct cell populations.
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Background: Some properties of mesenchymal stromal cells (MSCs) might
be particularly of interest after organ transplantation. The authors aimed to
report herein the long-term results of their first-in man, prospective, con-
trolled, phase-1 study evaluating the safety of a single third-party MSC infu-
sion after liver transplantation (LT).
Methods: Ten liver transplant recipients under standard immunosuppres-
sion received 1.5–3 9 106/kg unrelated third-party MSCs on post-operative
day 3 ! 2 and were prospectively compared to a control group of 10 liver
transplant recipients. Primary endpoints were set to prospectively detect
potential delayed side effects of MSC infusion, and particularly occurrence
of infections and cancers. As secondary endpoints, liver graft- and patient
survivals, graft rejection and function, occurrence of bile duct complications,
and development of anti-HLA antibodies against liver- or MSC-donors were
studied.
Results: There was no difference in overall rates of infection or cancer at 5
years of follow-up between the two groups. There was also no difference in
liver graft- and patient survivals, graft rejection, blood liver tests or occur-
rence of bile duct complications. The prevalence of de novo liver DSA
related to HLA-mismatches was two times higher in the MSC group com-
pared to the control group. Three patients of the MSC group (30%) devel-
oped at least 1 de novo HLA antibody against MSC-donor. All the de novo
class II HLA antibodies against MSC were linked to a shared HLA mismatch
between the liver and MSC donors and 75% of HLA class II shared-mis-
matches led to de novo HLA antibodies.
Conclusions: This long-term follow-up confirms the safety of one single
MSC infusion after LT. The potential interesting effects of MSC need to be
confirmed by prospective studies. The development of anti-HLA antibodies
against MSC donor should be further evaluated especially in case of shared
HLAmismatchesbetween graft- and MSC-donors, despite the fact that no
deleterious effect could be detected.
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Background: MACE rates within the first year after kidney transplantation
in North American centres are reported at between 7.0% and 8.7% but data
from European cohorts are lacking. The aim of this population-cohort analy-
sis was to determine MACE rates within the first year after kidney transplan-
tation in England.
Methodology: We obtained data for kidney transplant procedures per-
formed in England between 1st April 2002 and 31st March 2018. Data were
extracted from Hospital Episode Statistics using administrative ICD-10 and
OPCS-4 codes, with linkage to the national death registry. We excluded
age !18, repeat transplant in same period, multi-organ transplant and resi-
dence outside England. MACE was defined as any hospital admissions with
myocardial infarction, stroke, unstable angina, heart failure, any coronary
revascularisation procedure and/or any cardiovascular-related death. Uni-
variable/multivariable logistical regression analyses were conducted to
investigate the odds for MACE after kidney transplantation.
Results: Our study cohort comprised of 30,325 kidney transplant recipients.
MACE events occurred in 781 patients within the first-year post-transplanta-
tion (2.6% of all kidney transplant procedures). Of these events, 201
occurred during the index admission for surgery (representing 25.7% of
first-year MACE events and 0.7% of all kidney transplant procedures). Pre-
dictors of long-term mortality were age, non-White ethnicity, socio-economic
deprivation, deceased donor, pre-existing diabetes, increased Charlson
score, previous cardiac history and MACE within the first year (HR 2.59;
95% CI 2.34-2.88, P < 0.001). Patients who suffered a non-fatal MACE
within the first year had 1-, 3-, 5- and 10-year patient survival of 80.5%,
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